IL-2/LAK therapy for refractory acute monoblastic leukemia relapsing after unrelated allogeneic bone marrow transplantation

Abstract

Leukemia relapse is a major cause of treatment failure after allogeneic bone marrow transplantation. We administered recombinant interleukin-2 (rIL-2) to a patient who relapsed after unrelated allogeneic bone marrow transplantation (uBMT). While the number of peripheral blood monoblastic leukemia cells increased after administration of rIL-2, the patient achieved durable remission for 5 months after low-dose chemotherapy followed by adoptive transfer of engrafted graft-derived lymphokine-activated killer (LAK) cells. Following the disappearance of the blast cells, however, both cutaneous and liver GVHD were exacerbated. Administration of rIL-2 and adoptive transfer of graft-derived LAK cells are considered to be possible choices for the treatment of acute leukemia relapsing after uBMT when donor leukocyte transfusion is not available.

DOI: 10.1038/sj.bmt.1701550

Statistics

0100200'01'03'05'07'09'11'13'15'17
Citations per Year

123 Citations

Semantic Scholar estimates that this publication has 123 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Nagayama1999IL2LAKTF, title={IL-2/LAK therapy for refractory acute monoblastic leukemia relapsing after unrelated allogeneic bone marrow transplantation}, author={Hiroshi Nagayama and Shigeru Takahashi and Toru Takahashi and Kazuo Ogami and Kenji Ikebuchi and Akihiro Tojo and Kenji Tani and Shinji Asano}, journal={Bone Marrow Transplantation}, year={1999}, volume={23}, pages={183-185} }